<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bamodu OA</submitter><funding>Teh-Tzer Study Group for Human Medical Research Foundation (TMRF)</funding><pagination>3478</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8303483</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(14)</volume><pubmed_abstract>&lt;i>Background&lt;/i>: Testosterone plays a critical role in prostate development and pathology. However, the impact of the molecular interplay between testosterone-associated genes on therapy response and susceptibility to disease relapse in PCa patients remains underexplored. &lt;i>Objective&lt;/i>: This study investigated the role of dysregulated or aberrantly expressed testosterone-associated genes in the enhanced dissemination, phenoconversion, and therapy response of treatment-resistant advanced or recurrent PCa. &lt;i>Methods:&lt;/i> Employing a combination of multi-omics big data analyses, in vitro, ex vivo, and in vivo assays, we assessed the probable roles of HSD17B2, HSD17B3, SHBG, and SRD5A1-mediated testosterone metabolism in the progression, therapy response, and prognosis of advanced or cas</pubmed_abstract><journal>Cancers</journal><pubmed_title>Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.</pubmed_title><pmcid>PMC8303483</pmcid><funding_grant_id>A1091044</funding_grant_id><pubmed_authors>Chen KC</pubmed_authors><pubmed_authors>Wu WL</pubmed_authors><pubmed_authors>Lin CD</pubmed_authors><pubmed_authors>Hu SW</pubmed_authors><pubmed_authors>Wang YH</pubmed_authors><pubmed_authors>Wu CC</pubmed_authors><pubmed_authors>Bamodu OA</pubmed_authors><pubmed_authors>Tzou KY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer.</name><description>&lt;i>Background&lt;/i>: Testosterone plays a critical role in prostate development and pathology. However, the impact of the molecular interplay between testosterone-associated genes on therapy response and susceptibility to disease relapse in PCa patients remains underexplored. &lt;i>Objective&lt;/i>: This study investigated the role of dysregulated or aberrantly expressed testosterone-associated genes in the enhanced dissemination, phenoconversion, and therapy response of treatment-resistant advanced or recurrent PCa. &lt;i>Methods:&lt;/i> Employing a combination of multi-omics big data analyses, in vitro, ex vivo, and in vivo assays, we assessed the probable roles of HSD17B2, HSD17B3, SHBG, and SRD5A1-mediated testosterone metabolism in the progression, therapy response, and prognosis of advanced or cas</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2026-04-08T09:11:05.213Z</modification><creation>2022-02-11T00:09:01.039Z</creation></dates><accession>S-EPMC8303483</accession><cross_references><pubmed>34298692</pubmed><doi>10.3390/cancers13143478</doi></cross_references></HashMap>